Targeting mechanisms of medulloblastoma formation

髓母细胞瘤形成的靶向机制

基本信息

  • 批准号:
    9213395
  • 负责人:
  • 金额:
    $ 38.65万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-07-01 至 2021-06-30
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): There is an urgent need to develop novel therapies for patients with medulloblastoma (MB), the most common malignant central nervous system (CNS) tumor in children. Current treatments include surgery, radiotherapy, and chemotherapy and result in 5-year survival rates of 40-90% depending on subtype. Moreover, children suffer important morbidity secondary to treatment, including neurological, intellectual and physical disabilities. The overall purpose of the present project is to investigate the role of the Brain-specific Angiogenesis Inhibitor 1 (BAI1) in cerebellar development and susceptibility to transformation, and explore new therapies for MB based on the related mechanisms. BAI1 is an orphan seven transmembrane G protein-coupled receptor (GPCR) specifically expressed in the brain, and belonging to the adhesion-type sub-family. Our new preliminary data show that BAI1 expression is significantly reduced in patients with MBs, and the promoter is epigenetically silenced, suggesting that BAI1 loss may facilitate MB formation. To test this in the physiological setting, we generated Bai1 knockout (KO) mice and found haploinsufficiency of Bai1 dramatically accelerates MB tumorigenesis in Ptch1+/- transgenic mouse models of MB, the first demonstration that a reduction in Bai1 dosage can promote MB formation in vivo. Interestingly, we detected enhanced Gli1/2 expression and a thicker external granule layer (EGL) during early postnatal cerebellum development in the Bai1 KO mice. Therefore, our preliminary studies link BAI1 with cerebellar development and neoplastic transformation. Based on these results, we hypothesize that BAI1 is a tumor suppressor in the cerebellum and that restoration of its expression with epigenetic therapy may represent a novel therapeutic intervention for MB. To test our hypothesis, we propose the following aims: (i) determine whether Bai1 loss accelerates MB formation in mice through abnormal activation of a growth-signaling pathway in the developing cerebellum, (ii) determine how BAI1 restoration in human MB cells can inhibit their growth, and alter their tumorigenic properties, and (iii) define the mechanisms of BAI1 inactivation in MB, and determine whether epigenetic reactivation of BAI1 expression has therapeutic effects in vivo. These studies are important as they increase our knowledge about developmental neurobiology in the CNS, and may lead to the development of novel therapeutic approaches for patients with medulloblastoma.
 描述(由申请人提供):迫切需要为髓母细胞瘤(MB)患者开发新的治疗方法,MB是儿童中最常见的恶性中枢神经系统(CNS)肿瘤。目前的治疗方法包括手术、放疗和化疗,根据亚型的不同,5年生存率为40-90%。此外,儿童因治疗而发病率很高,包括神经、智力和身体残疾。本课题的总体目的是研究脑特异性血管生成抑制因子1(BAI 1)在小脑发育和转化易感性中的作用,并基于相关机制探索MB的新治疗方法。BAI 1是一种在脑内特异性表达的孤儿七跨膜G蛋白偶联受体(GPCR),属于粘附型亚家族。我们的新的初步数据显示,在MB患者中,BAI 1表达显著降低,并且启动子在表观遗传学上沉默,这表明BAI 1缺失可能促进MB形成。为了在生理环境中测试这一点,我们产生了Bai 1敲除(KO)小鼠,并发现Bai 1的单倍不足显著加速了MB的Ptch 1 +/-转基因小鼠模型中的MB肿瘤发生,这首次证明了Bai 1剂量的减少可以促进体内MB的形成。有趣的是,我们检测到增强的Gli 1/2表达和较厚的外部颗粒层(EGL)在出生后早期小脑发育的Bai 1 KO小鼠。因此,我们的初步研究与小脑发育和肿瘤转化的BAI 1。基于这些结果,我们假设BAI 1是小脑中的肿瘤抑制因子,并且通过表观遗传疗法恢复其表达可能代表MB的新的治疗干预。为了验证我们的假设,我们提出以下目标:(i)确定BAI 1丢失是否通过发育中小脑中生长信号传导途径的异常激活而加速小鼠中MB的形成,(ii)确定人MB细胞中BAI 1恢复如何能够抑制其生长并改变其致瘤特性,以及(iii)确定MB中BAI 1失活的机制,并确定BAI 1表达的表观遗传再激活是否具有体内治疗效果。这些研究很重要,因为它们增加了我们对中枢神经系统发育神经生物学的了解,并可能导致髓母细胞瘤患者新的治疗方法的发展。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ERWIN G VAN MEIR其他文献

ERWIN G VAN MEIR的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ERWIN G VAN MEIR', 18)}}的其他基金

Mechanisms underlying BAI1/ADGRB1 negative regulation of glioblastoma mesenchymal transition and invasion.
BAI1/ADGRB1 胶质母细胞瘤间质转化和侵袭负调控的机制。
  • 批准号:
    10034438
  • 财政年份:
    2021
  • 资助金额:
    $ 38.65万
  • 项目类别:
Mechanisms underlying BAI1/ADGRB1 negative regulation of glioblastoma mesenchymal transition and invasion.
BAI1/ADGRB1 胶质母细胞瘤间质转化和侵袭负调控的机制。
  • 批准号:
    10488569
  • 财政年份:
    2021
  • 资助金额:
    $ 38.65万
  • 项目类别:
Mechanisms underlying BAI1/ADGRB1 negative regulation of glioblastoma mesenchymal transition and invasion.
BAI1/ADGRB1 胶质母细胞瘤间质转化和侵袭负调控的机制。
  • 批准号:
    10687227
  • 财政年份:
    2021
  • 资助金额:
    $ 38.65万
  • 项目类别:
Targeting Mechanisms of Medulloblastoma Formation
髓母细胞瘤形成的靶向机制
  • 批准号:
    10179178
  • 财政年份:
    2020
  • 资助金额:
    $ 38.65万
  • 项目类别:
Evaluating ADGRB3 as a tumor suppressor epigenetically silenced in WNT medulloblastoma
评估 ADGRB3 作为 WNT 髓母细胞瘤中表观遗传沉默的肿瘤抑制因子
  • 批准号:
    9965891
  • 财政年份:
    2019
  • 资助金额:
    $ 38.65万
  • 项目类别:
Evaluating ADGRB3 as a tumor suppressor epigenetically silenced in WNT medulloblastoma
评估 ADGRB3 作为 WNT 髓母细胞瘤中表观遗传沉默的肿瘤抑制因子
  • 批准号:
    10358481
  • 财政年份:
    2019
  • 资助金额:
    $ 38.65万
  • 项目类别:
Evaluating ADGRB3 as a tumor suppressor epigenetically silenced in WNT medulloblastoma
评估 ADGRB3 作为 WNT 髓母细胞瘤中表观遗传沉默的肿瘤抑制因子
  • 批准号:
    10599504
  • 财政年份:
    2019
  • 资助金额:
    $ 38.65万
  • 项目类别:
Evaluating ADGRB3 as a tumor suppressor epigenetically silenced in WNT medulloblastoma
评估 ADGRB3 作为 WNT 髓母细胞瘤中表观遗传沉默的肿瘤抑制因子
  • 批准号:
    10057681
  • 财政年份:
    2019
  • 资助金额:
    $ 38.65万
  • 项目类别:
Evaluating ADGRB3 as a tumor suppressor epigenetically silenced in WNT medulloblastoma
评估 ADGRB3 作为 WNT 髓母细胞瘤中表观遗传沉默的肿瘤抑制因子
  • 批准号:
    10583473
  • 财政年份:
    2019
  • 资助金额:
    $ 38.65万
  • 项目类别:
Evaluating ADGRB3 as a tumor suppressor epigenetically silenced in WNT medulloblastoma
评估 ADGRB3 作为 WNT 髓母细胞瘤中表观遗传沉默的肿瘤抑制因子
  • 批准号:
    10738336
  • 财政年份:
    2019
  • 资助金额:
    $ 38.65万
  • 项目类别:

相似海外基金

How tensins transform focal adhesions into fibrillar adhesions and phase separate to form new adhesion signalling hubs.
张力蛋白如何将粘着斑转化为纤维状粘连并相分离以形成新的粘连信号中枢。
  • 批准号:
    BB/Y004841/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.65万
  • 项目类别:
    Research Grant
Defining a role for non-canonical mTORC1 activity at focal adhesions
定义非典型 mTORC1 活性在粘着斑中的作用
  • 批准号:
    BB/Y001427/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.65万
  • 项目类别:
    Research Grant
How tensins transform focal adhesions into fibrillar adhesions and phase separate to form new adhesion signalling hubs.
张力蛋白如何将粘着斑转化为纤维状粘连并相分离以形成新的粘连信号中枢。
  • 批准号:
    BB/Y005414/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.65万
  • 项目类别:
    Research Grant
Development of a single-use, ready-to-use, sterile, dual chamber, dual syringe sprayable hydrogel to prevent postsurgical cardiac adhesions.
开发一次性、即用型、无菌、双室、双注射器可喷雾水凝胶,以防止术后心脏粘连。
  • 批准号:
    10669829
  • 财政年份:
    2023
  • 资助金额:
    $ 38.65万
  • 项目类别:
Regulating axon guidance through local translation at adhesions
通过粘连处的局部翻译调节轴突引导
  • 批准号:
    10587090
  • 财政年份:
    2023
  • 资助金额:
    $ 38.65万
  • 项目类别:
Improving Maternal Outcomes of Cesarean Delivery with the Prevention of Postoperative Adhesions
通过预防术后粘连改善剖宫产的产妇结局
  • 批准号:
    10821599
  • 财政年份:
    2023
  • 资助金额:
    $ 38.65万
  • 项目类别:
Regulating axon guidance through local translation at adhesions
通过粘连处的局部翻译调节轴突引导
  • 批准号:
    10841832
  • 财政年份:
    2023
  • 资助金额:
    $ 38.65万
  • 项目类别:
Prevention of Intraabdominal Adhesions via Release of Novel Anti-Inflammatory from Surface Eroding Polymer Solid Barrier
通过从表面侵蚀聚合物固体屏障中释放新型抗炎剂来预防腹内粘连
  • 批准号:
    10532480
  • 财政年份:
    2022
  • 资助金额:
    $ 38.65万
  • 项目类别:
I-Corps: A Sprayable Tissue-Binding Hydrogel to Prevent Postsurgical Cardiac Adhesions
I-Corps:一种可喷雾的组织结合水凝胶,可防止术后心脏粘连
  • 批准号:
    10741261
  • 财政年份:
    2022
  • 资助金额:
    $ 38.65万
  • 项目类别:
Sprayable Polymer Blends for Prevention of Site Specific Surgical Adhesions
用于预防特定部位手术粘连的可喷涂聚合物共混物
  • 批准号:
    10674894
  • 财政年份:
    2022
  • 资助金额:
    $ 38.65万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了